Pharma

Your Article Summary

See Latest Articles

Gilead Sciences Announces Record Third Quarter 2009 Financial Results
Gilead, 10/21/09

Gilead Sciences, Inc. announced its results of operations for the quarter ended September, 2009. Total revenues for the third quarter of 2009 were $1.80 billion, up 31 percent compared to total revenues of $1.37 billion for the third quarter of 2008. Net income for the third quarter of 2009 was $673.0 million, or $0.72 per diluted share. Net income for the third quarter of 2008 was $495.9 million, or $0.52 per diluted share. Non–GAAP net income for the third quarter of 2009, which excludes after–tax acquisition–related expenses, restructuring expenses and stock–based compensation expenses, was $730.3 million, or $0.78 per diluted share.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

HP to Acquire Networking Firm 3Com
HealthDataManagement, 11/20/09

Protox Reports 2009 Third Quarter Results
Protox Therapeutics , 11/18/09

King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
King Pharmaceuticals, 11/16/09

 See all of Financial Reports